QURE Stock: Price, Earnings History and SEC Filings
uniQure N.V. (QURE) last traded at $24.83, down 1.86% on the latest session and up 2.8% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-1.22 against an analyst estimate of $-0.81, a miss of 50.6%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
QURE earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Jul 29, 2026 | $-1.22 | $-0.81 | -50.62% |
| Mar 2026 | May 5, 2026 | $-0.85 | $-0.88 | +3.41% |
| Dec 2025 | Mar 2, 2026 | $-0.56 | $-0.93 | +39.78% |
| Sep 2025 | Nov 10, 2025 | $-1.38 | $-0.85 | -62.35% |
QURE beat the analyst EPS estimate in 2 of its last 4 reported quarters. Source: Nasdaq.
How QURE reacts to earnings
Across its last 8 earnings releases, QURE moved 9.5% on average the next session, in either direction. It rose after 5 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-07-29 | Before open | +9.30% |
| 2026-05-05 | Before open | +2.32% |
| 2026-03-02 | Before open | -32.82% |
| 2025-11-10 | Before open | -5.90% |
| 2025-07-29 | Before open | -8.68% |
| 2025-05-09 | Before open | +4.41% |
| 2025-02-27 | Before open | +3.43% |
| 2024-11-05 | Before open | +8.99% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
Latest SEC filings for QURE
- 8-K · Sep 29, 2026Regulation FD disclosure, Financial statements and exhibits
- 8-K · Sep 2, 2026Regulation FD disclosure, Financial statements and exhibits
- 10-Q · Jul 29, 2026
- 8-K · Jul 29, 2026Results of operations, Financial statements and exhibits
- 8-K · Jun 24, 2026Material agreement, Other events, Financial statements and exhibits
- 424B5 · Jun 24, 2026
- 424B5 · Jun 22, 2026
- 8-K · Jun 22, 2026Regulation FD disclosure, Other events, Financial statements and exhibits
- 8-K · Jun 17, 2026Other events, Financial statements and exhibits
- 8-K · Jun 15, 2026Officer or director change, Bylaw change, Shareholder vote
Insider filing activity
QURE insiders filed 0 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
QURE news
- uniQure stock heads toward November 4 results updateNov 1, 2026 · ad-hoc-news.de
- 3 Promising Genomics Stocks to Add to Your Portfolio NowOct 30, 2026 · finance.yahoo.com
- uniQure (QURE) Stock Could Be Overvalued Despite A Securities InvestigationOct 29, 2026 · finance.yahoo.com
- What ClearPoint Neuro (CLPT) Said on Its Q3 Earnings CallOct 29, 2026 · marketbeat.com
- uniQure to Announce Third Quarter 2026 Financial ResultsOct 28, 2026 · finance.yahoo.com
About uniQure N.V.
uniQure N.V. (QURE) is a US-listed public company on Nasdaq. The SEC classifies its business as Pharmaceutical Preparations. Its fiscal year ends in December.